ESC Heart Failure最新文献

{"title":"Insights into clinical practice: A national survey on fluid intake management in heart failure.","authors":"Linn Höög, Anna Strömberg, Nana Waldréus, Carolin Nymark","doi":"10.1002/ehf2.15273","DOIUrl":"https://doi.org/10.1002/ehf2.15273","url":null,"abstract":"<p><strong>Aims: </strong>Due to insufficient evidence and a lack of cohesive guidelines, the management and use of fluid restriction in patients with heart failure (HF) may vary among healthcare professionals. However, the extent of this variation is unknown. The aim of this study was to describe physicians' and registered nurses' (RN) clinical practice regarding fluid intake and fluid restriction in adult patients with HF.</p><p><strong>Methods and results: </strong>Physicians and RNs treating patients with HF at 75 hospitals across all healthcare regions in Sweden were invited to answer a web-based survey regarding management on fluid intake and fluid restriction. Data were analysed with descriptive statistics and chi-square test. A total of 646 physicians and RNs across 45 hospitals in Sweden completed the survey. Significant differences in recommendations and management were found in relation to professional role, care setting and work experience. Overall, 93.8% recommend fluid restriction for all or some patients with HF. RNs recommend fluid restriction for all patients with HF to a significantly higher extent compared with physicians (34.5% vs. 14.9%; P < 0.001). Additionally, 49.2% believe that fluid restriction is an effective treatment strategy to prevent congestion, and 29.3% recommend fluid restriction routinely. One-third lacked knowledge of existing local guidelines regarding fluid restriction.</p><p><strong>Conclusions: </strong>This study shows that there are differences in clinical practice regarding healthcare professionals' recommendations on fluid intake and fluid restriction. These differences may result in patients with HF receiving varied and inconsistent care. Recommendations were primarily based on each healthcare professional's individual opinion rather than on evidence and guidelines.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival after myocardial infarction according to left ventricular function and heart failure symptoms.","authors":"Jarle Jortveit, Peder L Myhre, Kristian Berge, Sigrun Halvorsen","doi":"10.1002/ehf2.15265","DOIUrl":"https://doi.org/10.1002/ehf2.15265","url":null,"abstract":"<p><strong>Aims: </strong>Left ventricular (LV) dysfunction following acute myocardial infarction (AMI) is common even in the absence of signs and symptoms of heart failure (HF). Recent trials of patients with LV dysfunction post-AMI have demonstrated low event rates during follow-up. We aimed to assess the real-world prevalence and outcomes post-AMI, stratified by LV ejection fraction (LVEF) and the presence or absence of HF symptoms.</p><p><strong>Methods and results: </strong>Cohort study of patients with AMI registered in the Norwegian Myocardial Infarction Registry 2013-2022. Outcomes were short- and long-term all-cause mortality. Mortality was assessed by Kaplan-Meier survival curves, Life Table and multivariable Cox regression models.</p><p><strong>Results: </strong>Among 70 809 AMI patients (mean age 68.1 ± 12.9 years, 31% female), preserved (≥50%), mildly reduced (41%-49%) and reduced (≤40%) LVEF were present in 63.5%, 23.2% and 13.3%, respectively. Symptomatic HF was present in 3.3%, 28.1% and 63.2% of patients with preserved, mildly reduced and reduced LVEF. For each LVEF category, 1-year cumulative mortality rate from discharge was 3.9%, 7.8% and 17.8% for asymptomatic, and 16.2%, 13.7% and 20.2% for symptomatic patients, respectively. Symptomatic patients discharged alive had higher risk of mortality than asymptomatic: adjusted hazard ratio 1.85 (1.70-2.02) for preserved LVEF, 1.33 (1.25-1.41) for mildly reduced LVEF and 1.15 (1.06-1.24) for reduced LVEF.</p><p><strong>Conclusions: </strong>Reduced LVEF in the acute phase of AMI was associated with up to 20% 1-year mortality after discharge, substantially higher than in recent post-MI trials. Symptoms of HF during the index hospitalization were associated with worse outcomes in patients with preserved LVEF but contributed little additive risk for patients with reduced LVEF.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota and risk of heart failure in European population-A comprehensive Mendelian randomization study.","authors":"Liyan Huang, Xuemei Zhao, Jing Wang, Jingyuan Guan, Boping Huang, Jiayu Feng, Xinqing Li, Yuhui Zhang, Jian Zhang","doi":"10.1002/ehf2.15267","DOIUrl":"https://doi.org/10.1002/ehf2.15267","url":null,"abstract":"<p><strong>Aims: </strong>Gut dysbiosis is proven to be involved in the pathogenesis and progression of heart failure (HF). Hindering the detrimental effects of gut-heart axis is an emerging trend. Our goal is to investigate the causal relationship between gut microbiota and HF, with the aim of facilitating future exploration of microbiome-targeted approaches to prevent and delay the progression of HF.</p><p><strong>Methods and results: </strong>Two-sample Mendelian randomization (MR) analysis was applied to investigate the causal association of the gut microbiome with HF among individuals of European ancestry. Genetic variants associated with the 196 bacterial taxa from MiBioGen consortium were used as exposure data, summary statistics for HF derived from Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES) consortium were used as outcome data. Five MR methods were applied, including inverse variance weighted, maximum likelihood, MR-Egger, weighted median, and weighted mode. Reverse causality of instrumental variables (IVs) was tested by MR Steiger test of directionality. Strength of IVs was evaluated by F-statistics. Cochrane's Q test, MR-Egger regression analysis, and MR Pleiotropy RESidual Sum and Outlier (MR-PRESSO) tests were used to detect heterogeneity and pleiotropy. Leave-one-out method was used for testing the stability of results. Seven microbiomes were found to be associated with HF. Five of them were associated with higher risks of developing HF, these included Order_Selenomonadales (odds ratio [OR] = 1.11, P = 0.024), Family_Peptococcaceae (OR = 1.07, P = 0.045), Genus_Eubacterium eligens group (OR = 1.14, P = 0.022), Genus_Eubacterium oxidoreducens group (OR = 1.12, P = 0.011) and Genus_Flavonifractor (OR = 1.14, P = 0.012). Genus_Anaerostipes and Order_Bacillales were associated with lower risks of HF (OR = 0.90, P = 0.014; OR = 0.95, P = 0.042, respectively). Evidence of pleiotropy or heterogeneity was not observed.</p><p><strong>Conclusions: </strong>We identified seven intestinal microbiomes that were causally associated with HF at the level of gene prediction. This study will help with the discovery of potential preventive and therapeutic targets for HF.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk classification for long-term mortality among patients with acute heart failure: China PEACE 4YMortality.","authors":"Wei Wang, Lihua Zhang, Guangda He, Xiqian Huo, Lubi Lei, Jingkuo Li, Boxuan Pu, Yue Peng, Xin Yuan","doi":"10.1002/ehf2.15207","DOIUrl":"https://doi.org/10.1002/ehf2.15207","url":null,"abstract":"<p><strong>Aims: </strong>There are limited tools to predict long-term mortality among patients hospitalized with acute heart failure (AHF) in China. This study aimed to develop and validate a model to predict long-term mortality risk among patients who were hospitalized with AHF and discharged alive.</p><p><strong>Methods: </strong>We used data from China Patient-Centred Evaluative Assessment of Cardiac Events Prospective Heart Failure Study. Multivariate Cox proportional hazard model was used to develop and internal validate a model to predict 4 year mortality risk.</p><p><strong>Results: </strong>The study included 4875 patients hospitalized for AHF, of whom 2066 (42.38%) died within 4 years following admission, with a median survival time of 3.91 (interquartile range: 1.67, 4.00) years. We selected 13 predictors to establish the model, including age, medical history of hypertension, chronic obstructive pulmonary disease and HF, systolic blood pressure, blood urea nitrogen, albumin, high-sensitivity troponin T, N-terminal pro-brain natriuretic peptide, serum creatine, Kansas City Cardiomyopathy Questionnaire-12 score and left ventricular ejection fraction. The model showed a reasonable performance with the discrimination [C-index was 0.726 (95% confidence interval, CI: 0.714, 0.739) in the development cohort and 0.727 (95% CI: 0.708, 0.747) in the validation cohort]. We then built a point-based risk score algorithm and the patients were stratified to low-risk (0-14), intermediate-risk (15-19) and high-risk (≥20) groups.</p><p><strong>Conclusions: </strong>By using readily accessible predictors, we developed and validated a risk prediction model to predict 4 year mortality risk among patients who were hospitalized with AHF and discharged alive. This model proved beneficial for individual risk stratification and facilitating ongoing enhancements in patient outcomes.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Left atrial to coronary sinus shunting in more advanced heart failure with preserved ejection fraction.","authors":"Ryan J Tedford, Brian A Houston, JoAnn Lindenfeld, Rami Kahwash, Marcus A Urey, Nicholas S Amoroso, Benjamin Hibbert, Firas Zahr, William A Gray, Javed Butler","doi":"10.1002/ehf2.15270","DOIUrl":"https://doi.org/10.1002/ehf2.15270","url":null,"abstract":"<p><strong>Aims: </strong>Inter-atrial shunt device therapy has shown mixed results in clinical trials, with clinical 'non-responders' typically showing features of more advanced heart failure. We aimed to analyse the haemodynamic and clinical response of a novel left atrial to coronary sinus (LA-CS) shunt device in patients with higher natriuretic peptide (NP) levels, a marker of disease severity.</p><p><strong>Methods and results: </strong>An analysis population (n = 95) of patients from the ALT-FLOW early feasibility study with left ventricular ejection fraction >40% and 1-year follow up was analysed. The cohort was divided into low and high subgroups based on NP levels [b-type natriuretic peptide (BNP) and n-terminal pro BNP (NT-proBNP)]. The mean BNP and NT-proBNP levels for low versus high subgroups were 64.2 ± 34.3 versus 261 ± 103 and 322 ± 269 versus 2050 ± 1070 pg/mL, respectively. Patients in the high NP subgroup had evidence of more advanced disease including worse haemodynamic profiles, lower estimated glomerular filtration rate, and higher percentages of atrial fibrillation. The high NP subgroup experienced significant improvements in KCCQ-OSS and NYHA functional class (P < 0.0001 and P < 0.001, respectively) and to a similar magnitude compared with the low NP subgroup. Compared with pre-implant baseline, workload adjusted pulmonary artery wedge pressure at peak exercise declined in the high NP subgroup (PCWL, 164.1 vs. 96.0 mmHg/W/kg at 6 months, P < 0.003) as well as the low NP subgroup (115.9 vs. 65.9 mmHg/W/keg at 6 months, P < 0.001). Importantly, in both NP subgroups, there was preservation of cardiac index through 6 months as well as right ventricular structure (right ventricular diastolic dimension) and function (tricuspid annular systolic plane excursion) through 1 year.</p><p><strong>Conclusions: </strong>The quality-of-life, haemodynamic, and functional class improvements along with stable right heart function seen in ALT-FLOW study of LA-CS shunt remain consistent in the subgroup with highest NP levels. This suggests that shunting location could influence outcomes in symptomatic heart failure patients.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrial fibrillation development in the heart failure population from nationwide British linked electronic health records.","authors":"Hiroyuki Yoshimura, Nikhil Paliwal, Arturo Gonzalez-Izquierdo, Chris Finan, Amand Floriaan Schmidt, Gregory Y H Lip, Rui Providencia","doi":"10.1002/ehf2.15264","DOIUrl":"https://doi.org/10.1002/ehf2.15264","url":null,"abstract":"<p><strong>Aims: </strong>Atrial fibrillation (AF) is a frequent comorbidity in heart failure (HF). We analysed factors associated with new-onset atrial fibrillation in patients with heart failure using linked real-world UK data from primary and secondary care, along with findings from genome-wide association studies.</p><p><strong>Methods and results: </strong>Among 163 174 participants with a diagnosis of HF (January 1998 to May 2016) from Clinical Practice Research Datalink (CPRD) and Hospital Episodes Statistics (HES), 111 595 participants had no previous history of AF (mean age 76.3 ± 12.6; 50.3% women; 95.8% white ethnicity). Multivariate weighted Cox regression was used to identify predictors for new-onset AF. Linkage disequilibrium score regression was performed to assess the strength of the genetic correlation between AF and identified predictors. During follow-up (median 1.33 years, IQR 0.15-4.18), the incidence rate for AF was 2.8% at 30 days, 9.9% at 1 year, 18.0% at 3 years, and 24.9% at 5 years after HF diagnosis after HF diagnosis. Female sex (HR = 0.79, 95% CI 0.71-0.88), age (HR = 1.04, 95% CI 1.04-1.04), white ethnicity (HR = 1.30, 95% CI 1.06-1.59), social deprivation (HR = 1.20, 95% CI 1.01-1.42), BMI (HR = 1.01, 95% CI 1.00-1.02), gentle physical activity (HR = 0.84, 95% CI 0.72-0.97), hypertension (HR = 1.15, 95% CI 1.03-1.29), chronic kidney disease (HR = 1.15, 95% CI 1.06-1.24), chronic obstructive pulmonary disease (COPD) (HR = 1.10, 95% CI 1.01-1.19) and valvular heart disease (HR = 1.17, 95% CI 1.06-1.29) were associated with new-onset AF. Angiotensin-converting enzyme inhibitors were associated with lower AF incidence (HR = 0.88, 95% CI 0.80-0.96), and the magnitude of effect was dependent on the duration of administration. Linkage disequilibrium score regression showed important genetic correlation between AF and HF (rg = 0.57, P = 2.30 × 10^-59) and reduced, but still significant, overlap between AF and BMI (rg = 0.19, P = 6.18 × 10^-20), systolic and diastolic blood pressure, smoking, and COPD (P values ranging from <10^-4 to <0.05).</p><p><strong>Conclusions: </strong>Incident AF in the HF population is high, with good genetic correlation for the two conditions. Identified predictors for new-onset AF might be helpful to improve management of HF patients and AF prevention.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovering new hub genes of dilated cardiomyopathy.","authors":"Jun-Yan Zhu, Yu Han, Jing-Yu Yang, De-Ping Wang, Li-Juan Gao, Teng Sun, Yan-Lin Feng, Zhong-Mei He, Bin Zhou, Ji-Min Cao","doi":"10.1002/ehf2.15259","DOIUrl":"https://doi.org/10.1002/ehf2.15259","url":null,"abstract":"<p><strong>Aims: </strong>Dilated cardiomyopathy (DCM) has a poor prognosis and exhibits a complex and diverse aetiology and genetic profile. The genes responsible for the pathogenesis of DCM have not been fully identified. The present study aimed to explore new hub genes of DCM by mining the human DCM databases and further by experimental validation.</p><p><strong>Methods: </strong>Two gene expression profiles of human DCM (GSE9800 and GSE120895) in the Gene Expression Omnibus (GEO) database were analysed to identify the differentially expressed genes (DEGs) (DCM vs. normal) and to obtain the common DEGs (cDEGs, between GSE9800 and GSE120895) using bioinformatic methods. The cDEGs were subjected to Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, and the protein-protein interaction (PPI) networks and functional modules were constructed to screen the hub genes. The screened hub genes were identified using the Online Mendelian Inheritance in Man (OMIM) dataset, and their transcription and translation levels were further verified by real-time quantitative PCR (RT-qPCR) and western blotting using doxorubicin (DOX)-treated H9C2 cardiomyocytes that simulate the cellular pathology of DCM, with phosphate-buffered saline (PBS)-treated H9C2 cells as a normal control.</p><p><strong>Results: </strong>A total of 47 cDEGs were screened out, and 19 DCM-associated hub genes were identified. Among the 19 hub genes, 6 genes (NFKBIB, PSMC4, PSMD3, RAD21, PRNP and STAT2) have not yet been reported as associated with DCM. Among the six genes, NFKBIB and PRNP showed up-regulations, whereas PSMC4, PSMD3 and RAD21 exhibited down-regulations in their mRNA and protein expression levels in DOX-treated H9C2 cardiomyocytes compared with the control H9C2 cells (all P < 0.05). The remaining STAT2 showed a significant up-regulation in its protein expression (P < 0.05), while its mRNA up-regulation did not reach a statistical significance (P = 0.1082).</p><p><strong>Conclusions: </strong>Six new hub genes of DCM (NFKBIB, PSMC4, PSMD3, RAD21, PRNP and STAT2) were identified by bioinformatic analysis and experimental validation in this study. These hub genes or their products may potentially be new diagnostic biomarkers or therapeutic targets for DCM.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the link of malnutrition with diabetes and mortality risk in heart failure patients.","authors":"Konstantinos Prokopidis, Yang Chen, Yang Liu, Ziyi Zhong, Jordi Morwani-Mangnani, Daniel J Cuthbertson, Rajiv Sankaranarayanan, Gregory Y H Lip, Masoud Isanejad","doi":"10.1002/ehf2.15263","DOIUrl":"https://doi.org/10.1002/ehf2.15263","url":null,"abstract":"<p><strong>Aims: </strong>Malnutrition is increasingly recognized as a significant factor influencing the clinical outcomes of patients with heart failure (HF). Diabetes exacerbates risks like hospitalizations and mortality due to cardiovascular complications. The aim of this study was to explore the association of malnutrition with diabetes and its prognostic impact on all-cause and cardiovascular mortality in patients with HF, using the nutritional assessment tools, controlling nutritional status (CONUT) score and geriatric nutritional risk index (GNRI).</p><p><strong>Methods and results: </strong>Data were obtained from the National Health and Nutrition Examination Survey (1999-2018). Malnutrition was assessed using the CONUT score and GNRI. Multivariate logistic regression models were used to assess the association between malnutrition and diabetes. And Cox proportional hazards models were used to assess the risk of death from malnutrition combined with or without diabetes in HF separately. In addition, propensity score matching and inverse probability weighting were used to adjust for confounders for logistic regression model and Cox proportional hazards model analyses. Finally, subgroup analyses were performed. This study included 1501 HF participants (median age 70.0 years; 43.8% females), including 586 (39.0%) with diabetes. Continuous CONUT was significantly associated with diabetes in HF (OR 1.19, 95% CI: 1.08-1.32, P < 0.001) and remained significant after propensity score matching and inverse probability weighting. Similar relationships exist for categorized CONUT, but GNRI was not associated with diabetes in HF. Then, 1500 participants completed follow-up (5.6 [2.8-9.7] years). Elevated continuous CONUT was related to higher all-cause (HR = 1.18, 95% CI: 1.09-1.29, P < 0.001) and cardiovascular mortality (HR = 1.26, 95% CI: 1.12-1.42, P < 0.001) in HF patients with diabetes. And increased continuous CONUT was linked to higher all-cause (HR = 1.12, 95% CI: 1.03-1.22, P < 0.001) and cardiovascular mortality (HR = 1.20, 95% CI: 1.07-1.35, P < 0.001) in HF patients without diabetes. Similar relationships exist for categorized CONUT.</p><p><strong>Conclusions: </strong>Malnutrition assessed by CONUT is linked to higher diabetes prevalence in HF, influenced by altered albumin, cholesterol and lymphocyte levels. CONUT also predicts all-cause and cardiovascular mortality in HF with and without diabetes. Future research should consider dietary assessments and body composition analysis to assess malnutrition in HF patients.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence with the editor about the article 'Clinical implication of sarcopenia in patients with acute decompensated heart failure: Design and rationale'.","authors":"Wanglu Bian, Yanming Wu, Biao Wang","doi":"10.1002/ehf2.15276","DOIUrl":"https://doi.org/10.1002/ehf2.15276","url":null,"abstract":"","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do differences among heart failure patients affect their access to treatment?","authors":"Halit Emre Yalvaç, Bulent Gorenek","doi":"10.1002/ehf2.15271","DOIUrl":"https://doi.org/10.1002/ehf2.15271","url":null,"abstract":"","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}